Показано 0 из 0
Дата |
---|
10.05.2024 |
09.05.2024 |
08.05.2024 |
07.05.2024 |
06.05.2024 |
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.346
|
0.372
|
0.4168
|
0.364
|
0.4168
|
0.3719
|
|
|
14 549.34
|
63.00
|
0.4164
|
0.429
|
0.4051
|
0.394
|
0.4054
|
0.40
|
|
|
29 588.38
|
124.00
|
0.4031
|
0.485
|
0.405
|
0.4031
|
0.414
|
0.4132
|
|
|
12 534.12
|
59.00
|
0.361
|
0.438
|
0.4252
|
0.4011
|
0.4252
|
0.4025
|
|
|
1 356.89
|
41.00
|
0.4001
|
0.445
|
0.40
|
0.39
|
0.42
|
0.4199
|
|
|
14 089.22
|
104.00
|
0.351
|
0.415
|
0.4099
|
0.39
|
0.41
|
0.3969
|
|
|
9 287.81
|
87.00
|
0.405
|
0.465
|
0.419
|
0.4021
|
0.419
|
0.41
|
|
|
6 750.72
|
41.00
|
0.403
|
0.468
|
0.426
|
0.405
|
0.426
|
0.4081
|
|
|
6 636.95
|
61.00
|
0.4022
|
0.4395
|
0.44
|
0.4006
|
0.44
|
0.4159
|
|
|
6 919.40
|
65.00
|
0.4201
|
0.48
|
0.4725
|
0.4212
|
0.4725
|
0.44
|
|
|
8 572.30
|
110.00
|
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development.